Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis AstraZeneca and MedImmune, its global ...

Imfinzi met the second primary endpoint of overall survival which was both statistically-significant and clinically-meaningful at a planned interim analysis AstraZeneca and MedImmune, its global ...

IMFINZI is the only immunotherapy approved to treat patients in this curative-intent setting following chemoradiation therapy WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca today announced that ...

Imfinzi is a key revenue driver for AZN’s oncology portfolio, having generated sales worth $2.26 billion in the first half of 2024, up 25% year over year at constant exchange rates.

Durvalumab appeared associated with improved OS compared with placebo among patients with unresectable stage III non-small cell lung cancer whose disease had not progressed following platinum ...

The label expansion in first-line ES-SCLC may improve the prospect for Imfinzi going forward. AstraZeneca’s shares are down 14.8% so far this year compared with the industry’s decline of 15.5%.

The Food and Drug Administration (FDA) has granted Orphan Drug designation to Imfinzi (durvalumab; AstraZeneca) for the treatment of small cell lung cancer (SCLC). The multicenter, open label ...

References: Imfinzi ® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer. News release. AstraZeneca. June 17, 2024. https ...

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.